Survey of Canadian Physician Use of Botulinum Toxin A (BoNT-A) for Paratonia: Real World Insights-Reference-Cited by-同舟云学术

Survey of Canadian Physician Use of Botulinum Toxin A (BoNT-A) for Paratonia: Real World Insights

Published:2024-04-01 Issue: Volume: Page:1-4
ISSN:0317-1671
Container-title:Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
language:en
Short-container-title:Can. J. Neurol. Sci.

Author:

Kleiner Galit^ORCID,Ismail Farooq,Khan Omar,Pilieci Christopher,Truong Linda,Boulias Chris

Abstract

ABSTRACT: Paratonia is a form of hypertonia characterized by an inability to relax muscles in the setting of cognitive impairment. Paratonia results in pain, refusal of care, and caregiver burden. We sent surveys to 67 Canadian physiatrists and neurologists regarding their experience treating paratonia with botulinum toxin A (BoNT-A). Twenty-seven survey respondents were included in the analysis. Thirteen percent of survey respondents treating paratonia with BoNT-A reported a significant clinically relevant improvement; 74% endorsed a moderately clinically relevant improvement; 13% endorsed a slight clinically relevant improvement. Ninety percent of survey respondents endorsed significant barriers in treating paratonia with BoNT-A.

Publisher

Cambridge University Press (CUP)

Reference12 articles.

1. Paratonia

2. The Neurologic Syndrome of Severe Alzheimer's Disease

3. Prevalence of pressure ulcers in Canadian healthcare settings;Woodbury;Ostomy Wound Manage,2004

4. 8. Canadian Institute for Health Information. Dementia in long-term care. https://www.cihi.ca/en/dementia-in-canada/dementia-care-across-the-health-system/dementia-in-long-term-care. Accessed April 11, 2024.

5. Debilite mentale and debilite motrice associees;Dupre;Rev Neurol,1910